The University of Chicago Header Logo

Connection

Wendy Stock to Mutation

Back to Details
This is a "connection" page, showing publications Wendy Stock has written about Mutation.
Wendy Stock
Connection Strength
2.054
Mutation
  1. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
    View in: PubMed
    Score: 0.416
  2. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016 10; 57(10):2298-306.
    View in: PubMed
    Score: 0.236
  3. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214.
    View in: PubMed
    Score: 0.168
  4. Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nat Genet. 2024 Nov; 56(11):2434-2446.
    View in: PubMed
    Score: 0.107
  5. OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer J. 2021 03 03; 11(3):48.
    View in: PubMed
    Score: 0.083
  6. Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia. Blood. 2000 Apr 01; 95(7):2364-71.
    View in: PubMed
    Score: 0.078
  7. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. PLoS One. 2019; 14(10):e0224097.
    View in: PubMed
    Score: 0.076
  8. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):431-440.e13.
    View in: PubMed
    Score: 0.073
  9. Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):636-647.
    View in: PubMed
    Score: 0.069
  10. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016 11 24; 375(21):2023-2036.
    View in: PubMed
    Score: 0.062
  11. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget. 2015 Oct 20; 6(32):33410-25.
    View in: PubMed
    Score: 0.058
  12. Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. Leukemia. 2015 Oct; 29(10):2113-6.
    View in: PubMed
    Score: 0.055
  13. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014 Jul; 55(7):1523-32.
    View in: PubMed
    Score: 0.051
  14. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013 Mar; 45(3):242-52.
    View in: PubMed
    Score: 0.048
  15. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Oct; 59(4):662-7.
    View in: PubMed
    Score: 0.045
  16. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006 Jul 01; 108(1):28-37.
    View in: PubMed
    Score: 0.030
  17. Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv. 2024 10 22; 8(20):5297-5305.
    View in: PubMed
    Score: 0.027
  18. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv. 2024 01 23; 8(2):429-440.
    View in: PubMed
    Score: 0.026
  19. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
    View in: PubMed
    Score: 0.025
  20. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). Leukemia. 2024 01; 38(1):45-57.
    View in: PubMed
    Score: 0.025
  21. Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories. Blood Adv. 2023 10 24; 7(20):6048-6054.
    View in: PubMed
    Score: 0.025
  22. Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study. Blood Adv. 2023 08 22; 7(16):4671-4675.
    View in: PubMed
    Score: 0.025
  23. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
    View in: PubMed
    Score: 0.025
  24. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 2023 04; 37(4):788-798.
    View in: PubMed
    Score: 0.024
  25. Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. Mol Cell. 2021 09 16; 81(18):3833-3847.e11.
    View in: PubMed
    Score: 0.021
  26. Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. Nat Commun. 2021 02 26; 12(1):1334.
    View in: PubMed
    Score: 0.021
  27. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020 12; 26(12):1852-1858.
    View in: PubMed
    Score: 0.020
  28. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
    View in: PubMed
    Score: 0.020
  29. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019 02; 51(2):296-307.
    View in: PubMed
    Score: 0.018
  30. Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Adv. 2018 12 26; 2(24):3608-3617.
    View in: PubMed
    Score: 0.018
  31. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clin Cancer Res. 2018 05 15; 24(10):2294-2303.
    View in: PubMed
    Score: 0.017
  32. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016 Oct 18; 7(42):68833-68841.
    View in: PubMed
    Score: 0.015
  33. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014 Jan; 164(2):223-32.
    View in: PubMed
    Score: 0.013
  34. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
    View in: PubMed
    Score: 0.013
  35. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012 Nov 08; 120(19):3898-905.
    View in: PubMed
    Score: 0.012
  36. Treatment-influenced associations of PML-RARa mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood. 2012 Sep 06; 120(10):2098-108.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.